Galmed Pharmaceuticals Earnings Estimate

GLMD Stock  USD 0.61  0.06  8.96%   
By analyzing Galmed Pharmaceuticals' earnings estimates, investors can diagnose different trends across Galmed Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Galmed Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
 
Interest Hikes
Galmed Pharmaceuticals is projected to generate -0.5775 in earnings per share on the 31st of December 2025. Galmed Pharmaceuticals earnings estimates show analyst consensus about projected Galmed Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Galmed Pharmaceuticals' historical volatility. Many public companies, such as Galmed Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Galmed Pharmaceuticals' earnings estimates, investors can diagnose different trends across Galmed Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about (71 K). In addition to that, Pretax Profit Margin is expected to decline to -4.54Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

Galmed Pharmaceuticals Earnings per Share Projection vs Actual

About Galmed Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Galmed Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Galmed Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Galmed Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-180.4 M-171.4 M
Earnings Yield(2.91)(2.77)
Price Earnings Ratio(0.36)(0.37)
Price Earnings To Growth Ratio 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Biotechnology sector continue expanding? Could Galmed diversify its offerings? Factors like these will boost the valuation of Galmed Pharmaceuticals. Market participants price Galmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galmed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(3.44)
Return On Assets
(0.21)
Return On Equity
(0.46)
Galmed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Galmed's balance sheet. Smart investors calculate Galmed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Galmed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.